Modulation of P-glycoprotein expression in hyperthyroid rat tissues

Drug Metabolism and Disposition

Volumn 33, Issue 11, 2005, Pages 1584-1587

  Nishio, Naoki ^a   Katsura, Toshiya ^a   Ashida, Kayoko ^a   Okuda, Masahiro ^a   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BILE SALT; GLYCOPROTEIN P; ISOPROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTHYROIDISM; ILEUM; JEJUNUM; KIDNEY; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; GENE EXPRESSION REGULATION; HYPERTHYROIDISM; INTESTINES; KIDNEY; LIVER; MALE; P-GLYCOPROTEIN; P-GLYCOPROTEINS; RATS; RATS, WISTAR; RNA, MESSENGER; THYROXINE;

ANIMALIA;

EID: 27544455197     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.004770     Document Type: Article

References (25)

1. Ashida K, Katsura T, Motohashi H, Saito H, and Inui K (2002) Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. Am J Physiol 282:G617-G623.
2. Ashida K, Katsura T, Saito H, and Inui K (2004) Decreased activity and expression of intestinal oligopeptide transporter PEPT1 in rats with hyperthyroidism in vivo. Pharm Res (NY) 21:969-975.
3. Bonelli J, Haydl H, Hrudy K, and Kaik G (1978) The pharmacokinetics of digoxin in patients with manifest hyperthyroidism and after normalization of thyroid function. Int J Clin Pharmacol Biopharm 16:302-306.
4. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, and Klaassen CD (2002) Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30:838-844.
5. Childs S, Yeh RL, Georges E, and Ling V (1995) Identification of sister gene to P-glycoprotein. Cancer Res 55:2029-2034.
6. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
7. Fromm MF, Kim RB, Stein CM, Wilkinson GR, and Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport. A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557.
8. +-ATPase gene expression in rat intestine and Caco-2 cells: response to thyroid hormone. Am J Physiol 265:G775-G782.
9. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104:147-153.
10. Lawrence JR, Sumner DJ, Kalk WJ, Ratcliffe WA, Whiting B, Gray K, and Lindsay M (1977) Digoxin kinetics in patients with thyroid dysfunction. Clin Pharmacol Ther 22:7-13.
11. + exchanger (NHE1). J Biol Chem 277:28656-28662.
12. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, and Inui K (2000) Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 68:98-103.
13. Matosin-Matekalo M, Mesonero JE, Laroche TJ, Lacasa M, and Brot-Laroche E (1999) Glucose and thyroid hormone co-regulate the expression of the intestinal fructose transporter GLUT5. Biochem J 339:233-239.
14. O'Connor P and Feely J (1987) Clinical pharmacokinetics and endocrine disorders - therapeutic implications. Clin Pharmacokinet 13:345-364.
15. +/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun 220:848-852.
16. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T, and Hori R (1993) Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 266:1614-1619.
17. Ribeiro RCJ, Apriletti JW, West BL, Wagner RL, Fletterick RJ, Schaufele F, and Baxter JD (1995) The molecular biology of thyroid hormone action. Ann NY Acad Sci 758:366-389.
18. Shenfield GM (1981) Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 6:275-297.
19. Shenfield GM, Thompson J, and Horn DB (1977) Plasma and urinary digoxin in thyroid dysfunction. Eur J Clin Pharmacol 12:437-443.
20. Siegmund W, Altmannsberger S, Paneitz A, Hecker U, Zschiesche M, Franke G, Meng W, Warzok R, Schroeder E, Sperker B, et al. (2002) Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther 72:256-264.
21. 1). J Pharmacol Exp Ther 263:840-845.
22. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, and Inui K (1998) Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 64:123-128.
23. Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203-1211.
24. Zhang F, Riley J, and Gant TW (1996) Use of internally controlled reverse transcriptase-polymerase chain reaction for absolute quantitation of individual multidrug resistant gene transcripts in tissue samples. Electrophoresis 17:255-260.
25. Zhao JY, Ikeguchi M, Eckersberg T, and Kuo MT (1993) Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 133:521-528.